GE Healthcare wins FDA nod for Visipaque coronary CT angiography injection

GE Healthcare (NYSE:GE) said today that it won an indication approval from the FDA for its Visipaque injection imaging agent. The 320 milligram iodine per milliliter injection is an iso-osmolar agent that the federal watchdog approved for use in coronary computed tomography angiography.

The new indication allows doctors to image coronary arteries of patients to help diagnose coronary artery disease using a non-invasive technique. Traditionally, healthcare practitioners use invasive coronary angiography procedures to diagnose coronary artery disease.

Get the full story at our sister site, Drug Delivery Business News.

The post GE Healthcare wins FDA nod for Visipaque coronary CT angiography injection appeared first on MassDevice.

from MassDevice http://ift.tt/2pTiPu0